Ehave Provides Update on Companion Animal Informatics Platform to Include Use of Medical Cannabis

By August 14, 2018 Medical Cannabis, Press Releases

Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the medical cannabis and mental health communities with next-generation digital solutions, today gave an update on the development of its veterinary informatics solution for Companion Healthcare Technologies, Inc. (CHT), a company engaged in partnering, licensing and incubating cutting edge healthcare technologies to improve the quality of care for pets. CHT has licensed Ehave’s core health informatics platform, and the companies together have begun their work in developing a solution to effectively monitor, utilize, and improve therapeutic outcomes for pets by capturing and analyzing real-time, objective patient data.

CHT and Ehave have identified the emerging market opportunity for the use of medical cannabis in the care of companion animals, and the development of the informatics platform enhancements will incorporate the tracking of safety and efficacy data for animals who are prescribed cannabis. In addition, Ehave Connect platform’s capabilities in managing clinical trials will enable CHT’s customers to efficiently capture, track and manage high quality comprehensive data that can prove that cannabis works for pets.

“We have seen the recent market activity supporting the study and creation of safe and effective cannabis products for pets,” said Prateek Dwivedi, CEO of Ehave. “The Ehave platform for veterinary informatics that CHT has licensed will now embrace our core cannabis expertise. For day-to-day companion healthcare, trials of new cannabis therapies for pets, and the study of companion animals in pre-clinical trials for human cannabis therapeutics – the Ehave platform will ensure that reliable data exists a for clinicians to understand what to prescribe, pet owners to feel confident in treatments, and drug developers to design new therapies.”

Under the license agreement, CHT has exclusive rights to Ehave’s informatics platform for use, in any indication, in companion animals. Development has begun to integrate Ehave’s platform across the entire companion animal clinical pathway and related developments in the acceleration of quality of healthcare; allowing for consistent, consolidated data acquisition and analysis.

SUBSCRIBE TO RECEIVE NEWS AND INSIGHTS BY EMAIL

Ehave, Inc. (OTCQB: EHVVF) is empowering the medical cannabis and mental healthcare community with a next generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with leading medical cannabis licensed producers. www.ehave.com

Companion Healthcare Technologies, Inc. (“CHT”) is a private company engaged in partnering, licensing and incubating healthcare technologies with direct value to veterinary patients to improve the quality of care of companion animals and to improve treatment outcomes. CHT, along with its partner organizations, work closely with human healthcare companies and institutions to access cutting edge diagnostic and therapeutic products for translation to companion animal care. Companion Healthcare Technologies, Inc. (“CHT”) is a private company engaged in partnering, licensing and incubating healthcare technologies with direct value to veterinary patients to improve the quality of care of companion animals and to improve treatment outcomes. CHT, along with its partner organizations, work closely with human healthcare companies and institutions to access cutting edge diagnostic and therapeutic products for translation to companion animal care.

David Kugelman
dk@atlcp.com
(866) 692-6847

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.